Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Shares Outstanding (Weighted Average) (2017 - 2025)

Eton Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 8 years, with the latest figure at $26.9 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 3.91% to $26.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.9 million, a 3.91% increase, with the full-year FY2025 number at $26.9 million, up 7392.84% from a year prior.
  • Shares Outstanding (Weighted Average) hit $26.9 million in Q4 2025 for Eton Pharmaceuticals, roughly flat from $26.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for ETON hit a ceiling of $26.9 billion in Q2 2025 and a floor of $25133.0 in Q2 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $1.4 billion across 5 years, with a median of $25.2 million in 2021.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): tumbled 99.9% in 2023 and later soared 38756025.68% in 2025.
  • Tracing ETON's Shares Outstanding (Weighted Average) over 5 years: stood at $25.2 million in 2021, then decreased by 0.24% to $25.1 million in 2022, then grew by 1.99% to $25.6 million in 2023, then rose by 0.97% to $25.9 million in 2024, then rose by 3.91% to $26.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ETON at $26.9 million in Q4 2025, $26.9 million in Q3 2025, and $26.9 billion in Q2 2025.